Status:
TERMINATED
Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer
Lead Sponsor:
OHSU Knight Cancer Institute
Collaborating Sponsors:
Ortho Biotech, Inc.
Conditions:
Anemia
Fatigue
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
RATIONALE: Epoetin alfa may cause the body to make more red blood cells. It is used to treat anemia caused by cancer and chemotherapy. It may also help relieve fatigue in patients with anemia. PURPOS...
Detailed Description
OBJECTIVES: Primary * Determine the efficacy, in terms of maintenance of target hemoglobin and hematocrit levels, of interval dosing with epoetin alfa in treating patients with anemia undergoing che...
Eligibility Criteria
Inclusion
- ELIGIBILITY CRITERIA
- 18 years of age or greater
- Must have Hb less than 11 g/dl and normal hematopoesis
- Must have non-myeloid malignancies treated with myelosuppressive therapy \*Must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
- Must have a life expectancy of 6 months or greater
- Must have adequate liver function (bilirubin less than or equal to 2.0 mg) and renal function (creatinine less than or equal to 2.0 mg)
- Must have normal serum folate and vitamin B12 levels or be receiving replacement therapy
- Must be iron replete (transferring saturation great than or equal to 20 percent and ferritin greater than or equal to 100 mg/ml) or be receiving replacement therapy
- Must be able to fully comprehend and give written consent.
- Female patients with reproductive potential must be practicing an effective method of birth control (e.g., abstinence, prescription oral contraceptives, contraceptive injections, intrauterine device, double-barrier method, contraceptive patch, surgical sterilization) before entry and throughout the study.
- Female patients with reproductive potential must have a negative serum human chorionic gonadotropin (HCG) pregnancy test at screening (within 7 days before the first dose of study drug)
- Exclusion criteria
- Patient has uncontrolled hypertension
- Patient has history of symptomatic cardiac disease
- Patient has serious intercurrent illness
- The patient is pregnant, has a positive serum HCG or is lactating Patient has known hypersensitivity to mammalian cell-derived products or human albumin.
- Patient has diagnosis of polycythemia vera, chronic myelogenous leukemia, myelodysplastic syndrome
- May not be due for transplant within 24 weeks
- Anemia due to factors other than cancer.
- History of a thrombotic vascular event.
- History of seizures
- Patient has received a red blood cell growth factor (epoetin alfa or darbepoetin) within the last 60 days
Exclusion
Key Trial Info
Start Date :
May 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2008
Estimated Enrollment :
7 Patients enrolled
Trial Details
Trial ID
NCT00258440
Start Date
May 1 2003
End Date
September 1 2008
Last Update
May 9 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
OHSU Knight Cancer Institute
Portland, Oregon, United States, 97239-3098